Legal Risks for Hemp Companies: FDA Warning Letters and Compliance Trends

Focus keyword: FDA hemp compliance risks 2024

The regulatory landscape for hemp companies in 2024 is more turbulent than ever. With a surge in FDA warning letters and expanding compliance obligations, hemp and CBD businesses must stay sharply attuned to both federal and state requirements to avoid daunting civil and criminal penalties. Below, we analyze the most recent trends, guidance, and enforcement highlights impacting FDA hemp compliance risks 2024—providing essential insights for operators, compliance officers, and investors in the hemp sector.

Understanding Hemp Regulation Under the FDA

The Federal Baseline

Hemp and its derivatives—chiefly cannabidiol (CBD)—were removed from the Controlled Substances Act by the 2018 Farm Bill, provided products contain less than 0.3% Delta-9 THC. However, the FDA continues to regulate hemp-derived products under the Food, Drug, and Cosmetic Act (FDCA). This means:

• Dietary supplements containing CBD remain prohibited by the FDA,
• Food and beverage products with hemp-derived CBD are not recognized as GRAS (Generally Recognized as Safe),
• All hemp products are subject to the FDA’s rigorous standards regarding labeling, safety, and health claims (see official FDA guidance).

What’s New in 2024?

While hemp legalization had initially opened lucrative opportunities, 2024 has seen an escalation in:

• FDA enforcement actions—especially around product claims, misbranding, and manufacturing deficiencies.
• Legislation to close state and federal loopholes (including the ongoing debate on intoxicating cannabinoids and revised definitions for lawful hemp).
• Calls for clear FDA pathways for cannabinoids as dietary supplements or food products, which are still not in place as of September 2025 (Source).

Recent FDA Warning Letters: Trends and Examples

The FDA has publicly posted numerous warning letters to hemp and CBD companies in 2024 for violations including unsubstantiated therapeutic claims, misbranding, and adulteration (FDA source). Examples include:

• Koi CBD, LLC (CA) – Received an FDA warning for selling products with unapproved therapeutic claims on pain and anxiety (Koi CBD warning letter details).
• Discover Health, LLC (CO) – Targeted for marketing CBD products as treatments for diseases without proper clinical substantiation (Discover CBD).
• Purecraft LLC (CA) and Holista LLC – Cited for improper labeling, lack of evidence for claims, and violations of FDA safety standards.

A common thread in these letters is:

• Claims that products can treat, cure, or prevent diseases,
• Inadequate safety and efficacy data for products marketed as ingestibles,
• Manufacturing practices that do not comply with cGMP (current Good Manufacturing Practices) for dietary supplements.

Key Takeaway: If you’re marketing hemp-derived products, any hint of disease treatment or prevention in your marketing materials will draw FDA scrutiny.

Compliance Requirements in 2024 for Hemp Companies

Core FDA Compliance Areas

Labeling & Packaging:

• Do not claim to diagnose, cure, mitigate, treat, or prevent any disease unless FDA-approved.
• Product labels must include ingredient lists, manufacturer info, and comply with all FDA guidance on dietary supplements, foods, or cosmetics as relevant.
• Products purporting to be food or dietary supplements with CBD or other cannabinoids remain prohibited and at heightened risk for warning letters.

Manufacturing Practices:

• Adhere to cGMP guidelines for dietary supplements and the applicable subset for food products.
• Maintain robust batch testing, recall capabilities, and adverse event reporting protocols.
• Ensure purity and potency claims are backed by third-party lab testing (more on cGMP).

Marketing & Claims:

• Avoid all marketing statements suggesting efficacy for medical conditions or structured health benefits.
• Remove consumer testimonials if they imply medical treatment or health cures.
• Disclose product limitations, especially for minors, pregnant or nursing women, and potential drug interactions.

THC Content and Intoxicating Cannabinoids:

• Delta-8, Delta-10, and similar synthetic cannabinoids are under increased scrutiny and, in many states, outright bans.
• Randomized sampling and testing for compliance with the <0.3% THC threshold is essential for every batch.

Key Compliance Deadlines and Regulatory Changes

• No federal application window currently exists for FDA approval of ingestible CBD products as dietary supplements or food (as of September 2025).
• Pending congressional efforts could further restrict what qualifies as a hemp-derived cannabinoid at the federal level (more on this trend).
• Many state deadlines for product re-registration or testing apply—always cross-check with your state’s latest cannabis and hemp regulations (track with CannabisRegulations.ai).

Enforcement: FDA Penalties and What to Expect

Penalties for Non-Compliance

• Warning letters are the most common initial action, but repeated or severe violations can escalate to product seizures, injunctions, or even DOJ enforcement.
• Civil monetary penalties, forced recalls, and banishment from federal commerce are all potential consequences.
• State action may also follow, including license suspension or criminal penalties under misbranding or consumer fraud statutes.

Example: In November 2024, the FDA sent warning letters to at least 15 companies marketing CBD products for conditions such as pain, anxiety, or cancer—prompting some brands to remove affected products or update labeling to address FDA concerns (source).

Multi-Agency Scrutiny

• Expect collaboration between the FDA, FTC (for claims), state departments of agriculture, state cannabis control boards, and consumer protection bureaus. Dual state/federal enforcement is increasing.

Common Compliance Pitfalls for Hemp Businesses

• Overstating health benefits or including testimonials that infer disease treatment.
• Mislabeling CBD or other cannabinoids as “safe,” “natural,” or FDA-approved.
• Failing to implement recall, batch tracking, or adverse reaction reporting systems.
• Neglecting to monitor evolving state bans or restrictions on novel cannabinoids or certain product forms.

Proactive compliance not only mitigates legal risk but also positions your company as a trusted, sustainable operator.

Industry Trends: The Road Ahead

• Push for FDA-regulated pathways for CBD as a dietary supplement remains a top industry advocacy goal—but is still unresolved as of late 2025.
• States are enacting their own, often stricter, rules for labeling, manufacturing, and permitted cannabinoids. South Dakota, for example, has barred many hemp-derived products as of mid-2024 (read more).
• Calls to close the “hemp loophole” for intoxicating cannabinoids are gaining traction at the federal level, so expect dramatic shifts if Congress acts.

For operators, continuous monitoring of both FDA and state cannabis and hemp regulations is crucial.

Takeaways for Hemp Businesses and Investors

1. Do not market hemp-derived products with health, disease, or therapeutic claims.
2. Implement strict cGMP practices and third-party batch testing for all products.
3. Keep abreast of both FDA actions and state-level regulatory updates.
4. Respond immediately and transparently to any regulatory inquiry or warning letter.
5. Use robust labeling, marketing disclosure, and adverse event tracking systems.
6. Consult an expert in regulated product compliance for any new hemp-derived product rollout.

Stay Informed and Stay Compliant

Navigating the rapidly shifting terrain of FDA hemp compliance risks in 2024 demands vigilance, transparency, and commitment to best practices.

For up-to-date rule tracking, compliance guides, and state-by-state breakdowns, visit CannabisRegulations.ai and ensure your business remains ahead of the regulatory curve.

This article is for informational purposes only and does not constitute legal advice. For legal interpretation, consult a licensed attorney with cannabis and FDA regulatory expertise.